induces immune profile liposome-based vaccine adjuvant Th1-biased immune profile CAF09b vaccine adjuvant A vaccine adjuvant that is a lipid-based vaccine adjuvent based on cationic surfactant dimethyl-dioctadecyl ammonium (DDA) combined with C-type lectin agonist monomycoloyl glycerol (MMG) and TLR3 agonist poly I:C. CAF09b is able to induce CD8+ T-cell response. https://www.ncbi.nlm.nih.gov/pubmed/?term=35036074 Oliver He https://www.ncbi.nlm.nih.gov/pubmed/?term=33352684 Wolfgang Leitner VAC: https://vac.niaid.nih.gov/view?id=76 https://violinet.org/vaxjo/vaxjo_detail.php?c_vaxjo_id=152 76 https://www.ncbi.nlm.nih.gov/pubmed/?term=35163772 CAF09b Chemical Nature: Liposome Mechanism of Action: n/a Immune profile induced: n/a Route of immunization: IN, IP, IM, Point of Contact: Gabriel Kristian Pedersen, Staten Serum Institute (SSI) Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=35163772 https://www.ncbi.nlm.nih.gov/pubmed/?term=33352684 https://www.ncbi.nlm.nih.gov/pubmed/?term=35036074 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT03715985 vaccine adjuvant https://clinicaltrials.gov/ct2/show/NCT03715985 Ari Joffe Gabriel Kristian Pedersen